



I hereby certify that the correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on February 6, 2007.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1761
Patent Application
Docket No. SER-111
Serial No. 10/582,027

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Maria Dorly Del Curto
Serial No. : 10/582,027
Filed : June 8, 2006
Conf. No. : 1354
For : Stabilized Interferon Liquid Formulations

Mail Stop Amendment
Commissioner for Patents.
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicant has not submitted a copy of the U.S. patents cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)
Approved for use through 07/31/2005. OMB 9551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/582,027
Filing Date	June 8, 2006
First Named Inventor	Maria Dorly Del Curto
Art Unit	
Examiner Name	
Attorney Docket Number	SER-111

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/BH/	U1	US-5,997,856	12-07-1999	Hora <i>et al.</i>	All
/BH/	U2	US-6,582,728	06-24-2003	Platz <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁴
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
/BH/	F1	WO	03/002152 A2	01-09-2003	Maxygen APS	All	
▼	F2	WO	90/03784 A1	04-19-1990	Cetus Corporation	All	
	F3	WO	2005/117949 A1	12-15-2005	Ares Trading S.A.	All	
	F4						
	F5						
	F6						
	F7						

Examiner Signature	/Bruce Hissong/	Date Considered	06/18/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/582,027
Filing Date	June 8, 2006
First Named Inventor	Maria Dorly Del Curto
Group Art Unit	
Examiner Name	
Attorney Docket Number	SER-111

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BH/	R1	HULTGREN, C. <i>et al.</i> "The Antiviral Compound Ribavirin Modulates the T Helper (Th) 1/Th2 Subset Balance in Hepatitis B and C Virus-Specific Immune Responses", <i>Journal of General Virology</i> , 1998, pp. 2381-2391, Vol. 79.	
	R2	MARK, D. F. <i>et al.</i> "Site-Specific Mutagenesis of the Human Fibroblast Interferon Gene", <i>Proc. Natl. Acad. Sci. USA</i> , September 1984, pp. 5662-5666, Vol. 81.	
	R3	RUBINSTEIN, S. <i>et al.</i> "Convenient Assay for Interferons", <i>Journal of Virology</i> , February 1981, pp. 755-758, Vol. 37, No. 2.	
	R4	BREWSTER, M. E. <i>et al.</i> "Use of 2-Hydroxypropyl- β -cyclodextrin as a Solubilizing and Stabilizing Excipient for Protein Drugs", <i>Pharmaceutical Research</i> , 1991, pp. 792-795, Vol. 8, No. 6.	
	R5	ARAKAWA, T. <i>et al.</i> "Factors affecting short-term and long-term stabilities of proteins" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 307-326, Vol. 46, Nos. 1-3.	
	R6	IRIE, T. <i>et al.</i> "Cyclodextrins in peptide and protein delivery" <i>Advanced Drug Delivery Reviews</i> , 1999, pp. 101-123, Vol. 36.	
↓	R7	U.S. Application Serial No. 11/597,987 (claims only), filed November 30, 2006 (not yet published), pp. 1-4.	
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	/Bruce Hissong/	Date Considered	06/18/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.